脂肪乳治疗在致死性过量病例中的应用:一项观察性研究
该观察性研究从美国中毒控制中心协会国家中毒数据系统(AAPCC NPDS)提取2010-2015年叙述中出现「lipid」「ILE」或「fat」的病例,排除重复及未明确给予脂肪乳者,最终纳入459例。超过50%的病例涉及钙通道阻滞剂或β肾上腺素能拮抗剂,但不到25%的病例涉及脂肪乳工作组认为有证据支持其使用的物质。脂肪乳最常与多种治疗同时给予(277例)或作为最后手段(137例),127例在心脏骤停期间给予,34例作为一线治疗。反应率:无反应45%、反应未知38%、短暂/轻微反应7%、ROSC 7%、立即恶化3%;报告的可能不良反应包括ARDS 39例、脂血症导致实验室评估延迟3例、脂血症导致CRRT滤器失败2例、癫痫加重或新发2例、给药后立即心搏停止2例、脂肪栓塞1例。
要点
- 459例接受脂肪乳治疗的致死性中毒病例中,无反应率45%,反应未知38%,短暂/轻微反应仅7%,ROSC 7%,立即恶化3%。
- 超过50%的纳入病例涉及钙通道阻滞剂或β肾上腺素能拮抗剂,但不到25%的病例涉及脂肪乳工作组认为有证据支持其使用的物质。
- 脂肪乳最常与多种治疗同时给予(277例)或作为最后手段(137例),127例在心脏骤停期间给予,仅34例作为一线治疗。
- 报告的可能不良反应包括ARDS 39例、脂血症导致实验室评估延迟3例、脂血症导致CRRT滤器失败2例、癫痫加重或新发2例、给药后立即心搏停止2例、脂肪栓塞1例。
- 作者结论认为,已发表的脂肪乳治疗失败病例数超过成功病例数,非局麻药中毒中脂肪乳治疗的作用与疗效需要 robust 对照临床试验评估。
适用人群与场景
- 美国中毒控制中心协会国家中毒数据系统(AAPCC NPDS)2010-2015年数据中叙述出现「lipid」「ILE」或「fat」的致死性中毒病例,排除重复病例及未明确给予脂肪乳者,最终纳入459例。
研究设计与关键结果
- 研究类型为观察性研究,数据来源为AAPCC NPDS 2010-2015年,最终纳入459例接受脂肪乳治疗的致死性中毒病例。
- 超过50%的纳入病例涉及钙通道阻滞剂或β肾上腺素能拮抗剂,不到25%的病例涉及脂肪乳工作组认为有证据支持其使用的物质。
- 脂肪乳给药时机:与多种治疗同时给予277例,作为最后手段137例,心脏骤停期间127例,作为一线治疗34例。
- 反应率:无反应45%,反应未知38%,短暂/轻微反应7%,ROSC 7%,立即恶化3%。
- 可能的不良反应:ARDS 39例,脂血症导致实验室评估延迟3例,脂血症导致CRRT滤器失败2例,癫痫加重或新发2例,给药后立即心搏停止2例,脂肪栓塞1例。
证据类型、等级与局限
- 证据类型:观察性研究,基于AAPCC NPDS数据库。
- 作者结论指出,已发表的脂肪乳治疗失败病例数超过成功病例数,非局麻药中毒中脂肪乳治疗的作用与疗效需要 robust 对照临床试验评估。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,鉴于病例报告带来的不确定性,非局麻药中毒中脂肪乳治疗的作用与疗效需要 robust 对照临床试验评估。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Although anecdotal reports suggest that intravenous lipid emulsion (ILE) therapy is effective in a large variety of overdoses, the few controlled human trials published to date yielded disappointing results. Because of potential publication biases, there are few reports concerning the failure of ILE. The primary aim of this study was to identify fatal poisoning cases in the American Association of Poison Control Centers (AAPCC) National Poison Data System (NPDS) in which ILE was administered.
METHODS: We obtained an approved release of data from NPDS for years 2010-2015 in which the words "lipid," "ILE," or "fat" appeared in the narrative. Duplicate cases were excluded as were cases in which ILE was not clearly given. Case data were extracted by one author using a predetermined tool, and the information was confirmed by a second author. The timing of ILE administration was characterized into one of four categories: cardiac arrest, first line, last resort, or part of multiple therapies given simultaneously. Response to ILE and adverse events was recorded.
RESULTS: Of the 826 cases retrieved from NPDS, 459 met final inclusion criteria. Over 50% of included cases involved either a calcium channel blocker or a beta-adrenergic antagonist. Of note, less than 25% of cases involved a substance for which the Lipid Emulsion Working Group found evidence to support its use. Most often, ILE was given along with multiple therapies (277 cases) or as a last resort (137 cases). In 127 cases, ILE was given during cardiac arrest. ILE was used as first line therapy in 34 cases. Response rates were reported as follows: no response (45%), unknown response (38%), transient/minimal response (7%), ROSC (7%), and immediate worsening (3%). Possible adverse reactions included: ARDS in 39 patients, lipemia causing a delay in laboratory evaluation in three cases, lipemia causing failure of a CRRT filter in two cases, worsening or new onset seizure in two cases, asystole immediately after administration in two cases, and fat embolism in one case.
CONCLUSION: Within the Association of Poison Control Centers (AAPCC) National Poison Data System (NPDS), hundreds of cases exist in which ILE therapy was given and death occurred. In many of these cases, ILE was given prior to cardiovascular collapse. Although there is some suggestion of transient improvement in a small subset of cases, adverse effects are also reported. When taken in totality, the number of published cases of failed lipid emulsion therapy outnumbers the published instances of ILE success. Given all the uncertainty generated by case reports, the evaluation of the role and efficacy of ILE therapy in non-local anesthetic poisoning needs robust controlled clinical trials.
参考来源
- Smolinske S, Hoffman RS, Villeneuve E, et al. Utilization of lipid emulsion therapy in fatal overdose cases: an observational study. Clin Toxicol (Phila). 2018. PMID: 30260247. doi:10.1080/15563650.2018.1504954
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。